GlaxoSmithKline plc (GSK) Given New GBX 1,450 Price Target at Jefferies Group LLC
GlaxoSmithKline plc (LON:GSK) had its price target cut by Jefferies Group LLC from GBX 1,540 ($20.26) to GBX 1,450 ($19.07) in a research report released on Thursday. They currently have a buy rating on the stock.
GSK has been the topic of several other reports. Investec lowered shares of GlaxoSmithKline plc to a hold rating and cut their price target for the stock from GBX 1,800 ($23.67) to GBX 1,390 ($18.28) in a report on Monday, November 6th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.99) price target on shares of GlaxoSmithKline plc and gave the stock a buy rating in a report on Tuesday, August 8th. Deutsche Bank AG set a GBX 1,610 ($21.18) price target on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a report on Tuesday, August 8th. Citigroup Inc. reaffirmed a neutral rating on shares of GlaxoSmithKline plc in a report on Thursday, November 9th. Finally, Societe Generale reaffirmed a sell rating on shares of GlaxoSmithKline plc in a report on Thursday, November 9th. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the company’s stock. GlaxoSmithKline plc has an average rating of Hold and an average target price of GBX 1,569.75 ($20.65).
Shares of GlaxoSmithKline plc (LON GSK) traded down GBX 10 ($0.13) during trading hours on Thursday, reaching GBX 1,308 ($17.20). 6,441,460 shares of the company were exchanged, compared to its average volume of 9,720,000. GlaxoSmithKline plc has a 52 week low of GBX 1,311 ($17.24) and a 52 week high of GBX 1,724.50 ($22.68).
GlaxoSmithKline plc (LON:GSK) last issued its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) EPS for the quarter, topping analysts’ consensus estimates of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). The company had revenue of GBX 784.30 billion during the quarter. GlaxoSmithKline plc had a net margin of 17.79% and a return on equity of 461.88%.
The firm also recently declared a dividend, which will be paid on Thursday, January 11th. Shareholders of record on Thursday, November 9th will be issued a GBX 19 ($0.25) dividend. This represents a yield of 1.41%. The ex-dividend date of this dividend is Thursday, November 9th.
In other news, insider Simon Dingemans acquired 1,076 shares of the firm’s stock in a transaction on Thursday, October 12th. The stock was acquired at an average price of GBX 1,527 ($20.08) per share, for a total transaction of £16,430.52 ($21,610.57). Also, insider Urs Rohner acquired 473 shares of the firm’s stock in a transaction on Wednesday, October 25th. The stock was purchased at an average price of GBX 1,518 ($19.97) per share, with a total value of £7,180.14 ($9,443.82). In the last quarter, insiders acquired 1,576 shares of company stock valued at $2,400,376.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.